BioNTech (BNTX) Q1 FY26 earnings call

BioNTech continues to advance its oncology pipeline, focusing on combination therapies and late-stage assets like Pumitamig and Gotistobart, with several key data readouts expected in 2026. Despite a decline in Q1 COVID-19 vaccine revenues, the company reaffirmed its full-year guidance, supported by a strong balance sheet and a newly announced $1 billion share repurchase program. Strategic operational efficiency measures are also underway to optimize manufacturing and support future oncology commercialization.